Giving very late thrombolysis to patients with large-vessel occlusion small core strokes did not show a significant benefit in the TIMELESS trial. However, there were some encouraging trends, and ...

The bolus thrombolytic agent tenecteplase narrowly failed to show noninferiority to alteplase in the TASTE clinical trial within 4.5 hours of symptom onset selected by perfusion imaging in patients ...

Tenecteplase is an effective thrombolytic agent for eligible patients with stroke who are treated within 4.5 hours after the onset of stroke. However, data regarding the effectiveness of tenecteplase ...

Making the switch from alteplase to tenecteplase for stroke thrombolysis can be done successfully when the appropriate preparations are taken, and it may improve patient outcomes, the experience of a ...

Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...

Standard-dose tenecteplase (TNKase) beat low-dose alteplase as a bridge to stroke thrombectomy in bleeding-prone patients, a Japanese trial found. Early reperfusion outcomes significantly favored ...

Whether the evidence supports wider use of tenecteplase (TNKase; Genentech)—a thrombolytic agent with an indication for acute MI—as an alternative to alteplase (Activase; Genentech) for the treatment ...

Three years ago, 10 Ascension Seton hospitals made a change in the type of medication they gave people experiencing an ischemic stroke. The outcomes of that switch have now been published in the ...